20/20 Biolabs, Inc. (AIDX) stock
AIDXNasdaqServices-Testing LaboratoriesFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 16, 2026Score 6/3070% below fair value
$0.19−0.00 (-1.01%)
Close on Nov 18, 2026Market cap $2.37MP/E –Yield –
20/20 Biolabs free cash flow
Free cash flow is cash from operations minus capital expenditures: the cash available for dividends, buybacks, debt repayment or acquisitions.
No free cash flow figures for 20/20 Biolabs
20/20 Biolabs has not reported this figure in its SEC filings, or the share price needed to calculate it is not available yet.
See a number that looks wrong?